A recently published U.S. population-based cohort study found "significant reductions in 1-year cause-specific survival rates among patients diagnosed with both early-stage and late-stage cancer in 2020 and 2021." Compared to cancer patients diagnosed between 2015-2019, patients with a diagnosis of esophageal cancer (early-stage, 3.67%-3.89%), colorectal cancer (0.78%-1.08%) and prostate cancer (late-stage, 0.64%-0.77%)), were noted to have the largest site-specific survival reductions during the first 2 years of the COVID-19 pandemic. The authors of this cohort study thus propose that "swift action should be taken to increase cancer screening, rebuild healthcare capacity, and improve patient communication."
Source mentioned:
The pandemic-era survival drops are a sobering reminder that screening delays and disrupted care pathways cost lives even when the virus itself was not the cause. Esophageal, colorectal and prostate cancers showed the largest site-specific reductions, which points to where catch-up screening and rebuilt capacity matter most. Recovery-focused discussions on onc brothers often stress this point: restoring timely diagnosis is itself a cancer intervention.
ReplyDeleteWhat makes this study haunting is that the survival losses happened to people who were diagnosed — the failure was in the system around the diagnosis, not the diagnosis itself. The esophageal cancer figure, nearly a 4-point survival drop, is brutal for a disease where timely endoscopy is everything. The authors' three-part prescription — more screening, rebuilt capacity, better communication — reads like a warning about what the next disruption will cost if we do not fix the fragility now.
ReplyDelete